Exchange: NASDAQ·Updated 07:59 PM EDT

CRBU News

News
all
press releases
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sj?gren's trial was halted for futility; others also slid.read more...
Benzinga
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sj?gren's trial was halted for futility; others also slid.read more...
Benzinga
More News
CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs
Caribou said it would stop work on both of its clinical-stage CAR-T programs and consider strategic options including a merger, acquisition, or sale of assets.
Stocktwits
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why
Caribou Biosciences shares fall 35% after hours as the company weighs strategic alternatives and cuts two drug programs.read more...
Benzinga
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
Zacks
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows...
Yahoo! Finance: News

Advertisement|Remove ads.